Payment overview · 2025
General Payments
$481.99
21 reported records · 4 companies
Healthcare provider profile · identity verified
Allison Crain, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PHOENIX, AZ · NPI 1518221597
Verified facts
What the public records show
CMS Open Payments records show Allison Crain, M.D. received $481.99 in general payments during 2025 across 21 reported records.
ABBVIE INC. accounted for 44.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Nurtec Odt, Ozempic, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Qulipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $215.50 | 44.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $153.99 | 31.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $98.67 | 20.5% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.83 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $481.99 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $167.81 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $153.99 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $141.47 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.67 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.51 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $47.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.97 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 37 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 74 |
| Lisinopril | Lisinopril | 207 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 50 |
| Gabapentin | Gabapentin | 147 | 35 |
| Omeprazole | Omeprazole | 140 | 48 |
| Metformin Hcl | Metformin Hcl | 125 | 38 |
| Losartan Potassium | Losartan Potassium | 115 | 33 |
| Jardiance | Empagliflozin | 110 | 28 |
| Sertraline Hcl | Sertraline Hcl | 89 | 31 |
| Trulicity | Dulaglutide | 85 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 17 |
| Simvastatin | Simvastatin | 63 | 19 |
| Ozempic | Semaglutide | 59 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 15 |
| Famotidine | Famotidine | 54 | 19 |
| Carvedilol | Carvedilol | 52 | 15 |
| Metformin Hcl Er | Metformin Hcl | 49 | 14 |
| Montelukast Sodium | Montelukast Sodium | 47 | 17 |
| Bupropion Xl | Bupropion Hcl | 46 | 13 |
| Eliquis | Apixaban | 45 | 12 |
| Furosemide | Furosemide | 45 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 13 |
| Promethazine Hcl | Promethazine Hcl | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Qulipta | Atogepant | 42 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 14 |
| Botox | Onabotulinumtoxina | 37 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Acyclovir | Acyclovir | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | 12 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 24 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Valproate Sodium | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $481.99 · 21 records | ABBVIE INC. | BOTOX, Dexcom G6 Transmitter, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error